Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Venclexta (venetoclax)
Pharma
An Imbruvica combo regimen could have a new future in MCL
AbbVie is making the case for its Johnson & Johnson-partnered BTK inhibitor Imbruvica to stage a comeback in mantle cell lymphoma.
Fraiser Kansteiner
Dec 12, 2023 12:33pm
AbbVie, Roche's Venclexta disappoints in multiple myeloma trial
Sep 29, 2023 11:24am
NICE signs off on AbbVie, J&J's Imbruvica-Venclyxta combo in CLL
Apr 21, 2023 11:30am
AbbVie cancer survey reveals CLL emotional roller coaster
Aug 24, 2022 7:35am
J&J gets EMA backing for Imbruvica-venetoclax combination
Jun 28, 2022 10:05am
AbbVie, J&J eye new Imbruvica CLL use in fixed-duration combo
Jun 12, 2021 3:00am